Journal of Blood Medicine
Volume 11, 2020 - Issue
Open access
104
Views
0
CrossRef citations to date
0
Altmetric
Original Research
Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
Renchi Yang1 Thrombosis and Hemostasis Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People’s Republic of ChinaCorrespondence[email protected]
View further author information
, View further author information
Yongqiang Zhao2 Department of Hematology, Peking Union Medical College Hospital, Beijing, People’s Republic of ChinaView further author information
, Xuefeng Wang3 Department of Clinical Blood Transfusion, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
, Jing Sun4 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China
https://orcid.org/0000-0002-5130-4835View further author information
Runhui Wu5 Department of Hematology, Beijing Children’s Hospital and Capital Medical University, Beijing, People’s Republic of ChinaView further author information
, Chenghao Jin6 Department of Hematology, Jiangxi Provincial People’s Hospital, Jiangxi, People’s Republic of ChinaView further author information
, Jie Jin7 Department of Hematology, The First Affiliated Hospital – Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaView further author information
, Depei Wu8 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information
, Pablo Rendo9 Rare Disease, Pfizer Inc, Collegeville, PA, USAView further author information
, Feifei Sun10 Pfizer (China) Research & Development Co, Ltd, Shanghai, People’s Republic of ChinaView further author information
, Jeremy Rupon9 Rare Disease, Pfizer Inc, Collegeville, PA, USAView further author information
, Francois Huard11 Clinical Pharmacology, Pfizer PIO, Paris, FranceView further author information
, Joan M Korth-Bradley12 Pfizer Inc, Collegeville, PA, USAView further author information
, Lihong Xu10 Pfizer (China) Research & Development Co, Ltd, Shanghai, People’s Republic of China
https://orcid.org/0000-0002-9334-1271View further author information
Binyu Luo10 Pfizer (China) Research & Development Co, Ltd, Shanghai, People’s Republic of ChinaView further author information
& Yingxue Cathy Liu13 Statistics, Pfizer (China) Research & Development Co, Ltd, Shanghai, People’s Republic of ChinaView further author information
show all
Pages 439-448
|
Published online: 25 Nov 2020
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.